Differential expression of bcl-2 and bax in squamous cell carcinomas of the oral cavity

European Journal of Cancer Part B: Oral Oncology

Volumn 32, Issue 6, 1996, Pages 394-400

  Jordan, Richard C K ^a,b   Catzavelos, G C ^a   Barrett, A W ^b   Speight, P M ^b  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Apoptosis; Bax; bcl 2; Carcinoma; Tumour differentiation

Indexed keywords

PROTEIN BAX; PROTEIN BCL 2;

ADULT; AGED; APOPTOSIS; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MOUTH CARCINOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; BCL-2-ASSOCIATED X PROTEIN; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; UP-REGULATION;

EID: 0030294041     PISSN: 09641955     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0964-1955(96)00033-4     Document Type: Article

References (38)

1. 1. Boyle P, Macfarlane GJ, Maisonneuve P, Zheng T, Scully C, Tedesco B. Epidemiology of mouth cancer in 1989: a review. J R Soc Med 1990, 83, 724-730.
2. 2. Field JK. Oncogenes and tumour-suppressor genes in squamous cell carcinoma of the head and neck. Oral Oncol, Eur J Cancer 1992, 28B, 67-76.
3. 3. Field JK, Spandidos DA, Stell PM. Overexpression of the p53 gene in head and neck cancer, linked with heavy smoking and drinking. Lancet 1992, 339, 502-503.
4. 4. Brennan JA, Mao L, Hruban RH, et al. Molecular assessment of histopathological staging in squamous cell carcinoma of the head and neck. N Engl J Med 1995, 332, 429-435.
5. 5. Tsujimoto Y, Gorham J, Cossman J, Jaffe E, Croce CM. The t(14;18) chromosome translocations involved in B-cell neoplasms results from mistakes in VDJ joining. Science 1985, 299, 1390-1393.
6. 6. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 1986, 47, 19-28.
7. 7. Pezzella F, Ralfkiaer E, Gatter KC, Mason DY. The 14;18 translocation European cases of follicular lymphoma: comparison of Southern blotting and polymerase chain reaction. Br J Haematol 1990, 76, 58-64.
8. 8. Aisenberg AC, Wilkes BM, Jacobson JO. The bcl-2 gene is rearranged in many diffuse B-cell lymphomas. Blood 1988, 71, 969-972.
9. 9. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986, 83, 5214-5218.
10. 10. Hockenbery DM, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990, 348, 334-336.
11. 11. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991, 88, 6961-6965.
12. 12. Lu Q, Poulsom R, Wong L, Hanby AM. bcl-2 Expression in adult and embryonic non-haematopoietic tissues. J Pathol 1993, 169, 431-437.
13. 13. Pilotti S, Collini P, Cattorerti G, Del Bo R, Pierotti MA. bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol 1994, 172, 337-342.
14. 14. Ikegaki N, Katsumata M, Minna J, Tsujimoto Y. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 1994, 54, 6-8.
15. 15. Leek RD, Kaklamanis L, Pezzella F, Gatter KC, Harris AL. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br J Cancer 1004, 69, 135-139.
16. 16. Lu QL, Elia G, Lucas S, Thomas JA. bcl-2 proto-oncogene expression in Epstein-Barr virus-associated nasopharyngeal carcinoma. Int J Cancer 1993, 53, 29-35.
17. 17. Pezzella F, Turley H, Kuzu I, et al. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993, 329, 690-694.
18. 18. Yunis JJ, Mayer MG, Arensen MA, Aeppli DP, Oken MM, Frizzera G. bcl-2 and other genomic alterations in the prognosis of large cell lymphomas. N Engl J Med 1989, 320, 1047-1054.
19. 19. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992, 52, 6940-6944.
20. 20. Campos L, Roualult J, Sabido O, et al. High expression of bcl-2 in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993, 18, 3091-3096.
21. 21. Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC. Immunohistochemical determination of in vivo distribution of bax, a dominant inhibitor of bcl-2. Am J Pathol 1994, 145, 1323-1336.
22. 22. Oltvai ZN, Milliman CL, Korsmeyer SJ. bcl-2 heterodimerizes in vivo with a conserved homolog, bax, that accelerates programmed cell death. Cell 1993, 74, 609-619.
23. 23. Wahl PN, Cohen B, Luthra UK, Torloni H Histological Typing of Oral and Oropharyngeal Tumours. Geneva, WHO 1971, 17-18.
24. 24. Norton AJ, Jordan S, Yeomans P. Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J Pathol 1994, 173, 371-379.
25. 25. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981, 29, 577-580.
26. 26. Nakagawa K, Yamamura K, Maeda S, Ichihashi M. bcl-2 expression in epidermal keratinocytic diseases. Cancer 1994, 74, 1720-1724.
27. 27. Korsmeyer SJ. bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992, 80, 879-886.
28. 28. Pezzella F, Tse AGD, Cordel JL, Pulford KAF, Gatter KC, Mason DY. Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation. Am J Pathol 1990, 137, 225-232.
29. 29. Ramsay JA, From L, Kahn HJ. bcl-2 protein expression in melanocytic neoplasms of the skin. Modern Pathol 1995, 2, 150-154.
30. 30. Pezzella F, Turley H, Kuzu I, et al. bcl-2 protein in non-small-cell lung. N Engl J Med 1993, 329, 690-694.
31. 31. Castle VP, Heidelberger KP, Bromberg J, Ou XG, Dole M, Nunez G. Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification. Am J Pathol 1993, 143, 1543-1550.
32. 32. McCall CA, Cohen JJ. Programmed cell death in terminally differentiating keratinocytes: role of endogenous endonuclease. J Invest Dermatol 1991, 97, 111-114.
33. 33. Lumerman H, Freedman P, Kerpel S. Oral epithelial dysplasia and the development of invasive squamous cell carcinoma. Oral Surg Oral Med Oral Pathol 1995, 79, 321-329.
34. 34. Voravud N, Shin DM, Ro JY, Lee JS, Hong WK, Hittelman WN. Increased polysomies of chromosomes 7 and 17 during head and neck multistage tumongenesis. Cancer Res 1993, 53, 2874-2883.
35. 35. Ogden GR, Kiddie RA, Lunny DP, Lane DP. Assessment of p53 protein expression in normal, benign, and malignant oral mucosa. J Pathol 1992, 166, 389-394.
36. 36. Huang WY, Coltrera M, Schubert M, Morton T, Truelove E. Histopathologic evaluation of proliferating cell nuclear antigen (PC10) in oral epithelial hyperplasias and premalignant lesions. Oral Surg Oral Med Oral Pathol 1994, 78, 748-754.
37. 37. Bronner MP, Culin C, Reed JC, Furth EE. The bcl-2 protooncogene and the gastrointestinal epithelial tumor progression model. Am J Pathol 1995, 146, 20-26.
38. 38. Lauwers GY, Scott GV, Hendricks J. Immunohistochemical evidence of aberrant bcl-2 protein expression in gastric epithelial dysplasia. Cancer 1994, 73, 2900-2904.